Table 4.
In vitro cytokine production by PB T-cells of the patient and her relatives after polyclonal (PMA + ionomycin) and after antigen-specific stimulation (whole CMV lysate).
| Cytokine | Subset | Healthy adults (n = 5) | Patient | Daughter | Son | Mother | Father | Brother |
|---|---|---|---|---|---|---|---|---|
| POLYCLONAL STIMULATION (PMA + IONOMYCIN) | ||||||||
| IFNγ | CD8+ T-cells | 26–67% | 39% | 26% | 32% | 81% | 76% | 76% |
| CD4+ T-cells | 19–32% | 44%* | 22% | 45% | 38% | 27% | 34% | |
| IL-4/IL-5 | CD8+ T-cells | 0.1–0.3% | 0.5% | 0.1% | 0.3% | 0.4% | 0.1% | 0.6% |
| CD4+ T-cells | 1.6–2.9% | 4%* | 1.1% | 2.6% | 1.7% | 1% | 2.1% | |
| IL-17A/IL-17F | CD8+ T-cells | 0.2–1.3% | 5% | 0.7% | 3.2% | 6.3% | 9% | 5.7% |
| CD4+ T-cells | 1.4–2.5% | 5%* | 3% | 14% | 5.8% | 6% | 7.2% | |
| ANTIGEN-SPECIFIC STIMULATION (CMV) | ||||||||
| IFNγ | CD8+ T-cells | 0.3–0.7% | 0.8% | 0% | 0.2% | 1% | 2.9% | 0.3% |
| CD4+ T-cells | 0.5–5% | 0.4%* | 0.4% | 4.8% | 1.6% | 1.6% | 1% | |
| IL-4/IL-5 | CD8+ T-cells | 0–0% | 0% | 0% | 0% | 0% | 0% | 0.6% |
| CD4+ T-cells | 0–0.2% | 0.1%* | 0% | 0% | 0% | 0.2% | 0% | |
| IL-17A/IL-17F | CD8+ T-cells | 0–0% | 0% | 0% | 0% | 0% | 0% | 0.05% |
| CD4+ T-cells | 0–0% | 0.4%* | 0% | 0% | 0% | 0% | 0.08% | |
Results expressed as percentage of cells positive for each cytokine in CD8+, CD4+ T-cells and double-negative T-cells (DNTs).
*
Results from double CD4− CD8− TCRγδ− T-cells.